Key Points
- Adam Crystal sold 20,251 shares of Tango Therapeutics on March 5 at an average price of $15.00 for $303,765, leaving him with 112,622 shares (a 15.24% reduction); he also sold 54,345 shares on Feb 25 and 18,452 shares on Feb 3.
- TNGX shares opened at $16.45 with a 50‑day/200‑day SMA of $12.02/$9.54, a market cap of $2.35B and a 52‑week range of $1.03–$17.63; the company beat EPS estimates for the quarter ($0.29 loss vs. $0.31 expected) but remains unprofitable with deeply negative margins and ROE.
- Large institutions meaningfully increased positions in Q4 (e.g., Farallon, Adage, Siren, Vanguard, State Street) — institutional ownership is ~78.99% — and analysts maintain a consensus "Moderate Buy" with an average target of $19.38 after several upgraded price targets.
Tango Therapeutics, Inc. (NASDAQ:TNGX - Get Free Report) insider Adam Crystal sold 20,251 shares of the firm's stock in a transaction that occurred on Thursday, March 5th. The shares were sold at an average price of $15.00, for a total value of $303,765.00. Following the completion of the sale, the insider owned 112,622 shares in the company, valued at approximately $1,689,330. This represents a 15.24% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.
Adam Crystal also recently made the following trade(s):
- On Wednesday, February 25th, Adam Crystal sold 54,345 shares of Tango Therapeutics stock. The stock was sold at an average price of $12.77, for a total value of $693,985.65.
- On Tuesday, February 3rd, Adam Crystal sold 18,452 shares of Tango Therapeutics stock. The shares were sold at an average price of $12.26, for a total value of $226,221.52.
Tango Therapeutics Stock Down 2.9%
TNGX stock opened at $16.45 on Tuesday. The company has a 50-day simple moving average of $12.02 and a 200 day simple moving average of $9.54. The company has a market capitalization of $2.35 billion, a P/E ratio of -18.91 and a beta of 1.76. Tango Therapeutics, Inc. has a fifty-two week low of $1.03 and a fifty-two week high of $17.63.
Tango Therapeutics (NASDAQ:TNGX - Get Free Report) last released its quarterly earnings results on Thursday, March 5th. The company reported ($0.29) EPS for the quarter, topping analysts' consensus estimates of ($0.31) by $0.02. Tango Therapeutics had a negative net margin of 151.15% and a negative return on equity of 50.30%. Equities analysts anticipate that Tango Therapeutics, Inc. will post -1.19 EPS for the current year.
Institutional Investors Weigh In On Tango Therapeutics
Large investors have recently modified their holdings of the stock. Farallon Capital Management LLC raised its position in shares of Tango Therapeutics by 21.4% during the fourth quarter. Farallon Capital Management LLC now owns 13,061,411 shares of the company's stock worth $115,724,000 after purchasing an additional 2,304,411 shares during the period. Adage Capital Partners GP L.L.C. increased its stake in Tango Therapeutics by 322.5% in the 4th quarter. Adage Capital Partners GP L.L.C. now owns 10,607,924 shares of the company's stock worth $93,986,000 after purchasing an additional 8,096,924 shares in the last quarter. Siren L.L.C. raised its holdings in Tango Therapeutics by 38.8% during the 4th quarter. Siren L.L.C. now owns 8,165,374 shares of the company's stock worth $72,345,000 after buying an additional 2,282,186 shares during the period. Vanguard Group Inc. raised its holdings in Tango Therapeutics by 33.6% during the 4th quarter. Vanguard Group Inc. now owns 6,750,977 shares of the company's stock worth $59,814,000 after buying an additional 1,698,974 shares during the period. Finally, State Street Corp lifted its stake in Tango Therapeutics by 84.8% during the fourth quarter. State Street Corp now owns 6,218,567 shares of the company's stock valued at $55,097,000 after buying an additional 2,853,362 shares in the last quarter. 78.99% of the stock is owned by institutional investors.
Wall Street Analyst Weigh In
TNGX has been the subject of a number of research analyst reports. Wall Street Zen downgraded Tango Therapeutics from a "buy" rating to a "hold" rating in a research report on Saturday. Guggenheim boosted their price objective on Tango Therapeutics from $18.00 to $20.00 and gave the stock a "buy" rating in a research note on Friday. HC Wainwright upped their price objective on Tango Therapeutics from $13.00 to $27.00 and gave the company a "buy" rating in a report on Friday. Weiss Ratings reaffirmed a "sell (e+)" rating on shares of Tango Therapeutics in a report on Wednesday, January 21st. Finally, B. Riley Financial boosted their price target on shares of Tango Therapeutics from $8.00 to $14.00 and gave the stock a "buy" rating in a research report on Tuesday, November 18th. Nine analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company's stock. According to data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and a consensus target price of $19.38.
View Our Latest Report on TNGX
About Tango Therapeutics
(
Get Free Report)
Tango Therapeutics is a clinical-stage biotechnology company dedicated to developing precision medicines that exploit genetic vulnerabilities in cancer cells. Leveraging a proprietary synthetic lethality platform, the company identifies and targets tumor-specific dependencies in DNA damage response and related pathways. By focusing on tumor cell collateral sensitivities, Tango aims to bring differentiated small-molecule therapies to patients with genetic alterations that confer increased susceptibility to targeted inhibition.
The company's lead pipeline comprises several early-stage programs, including inhibitors designed to selectively disable DNA repair proteins in tumor cells while sparing normal tissues.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
